Solventum

SOLV · NYSE

$86.39+$1.34 (+1.58%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $85.05

SOLV analyst rating

HoldConsensus of 11 analysts over the last 12 months. 64% rate it a buy.

Strong buy0
Buy7
Hold3
Underperform0
Sell1

12-month price target · 16 analysts

Average $95.90 (+11.0% upside)

Low: $70.70
Now: $86.39
High: $118.65

Upgrades and downgrades

The latest rating actions, newest first

SOLV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Sep 14, 2026	Maintains	Buy	$95.00	48%
UBS	Aug 6, 2026	Maintains	Buy	$95.00 → $101.00	70%
Piper Sandler	Aug 6, 2026	Maintains	Overweight	$92.00 → $105.00	43%
Wedbush	Aug 6, 2026	Maintains	Outperform	$94.00 → $101.00	35%
Keybanc	Aug 6, 2026	Maintains	Overweight	$93.00 → $102.00	56%
Stifel	Aug 6, 2026	Maintains	Buy	$90.00 → $100.00	62%
BTIG	Aug 6, 2026	Maintains	Buy	$91.00 → $95.00	48%
UBS	Jul 28, 2026	Upgrade	Neutral → Buy	$95.00	70%
BMO Capital	Jul 9, 2026	Initiates	Market Perform	$81.00	—
Wedbush	May 15, 2026	Initiates	Outperform	$94.00	35%

The case for and against

Updated Oct 16, 2026

Bull case

Solventum is attractive because its simplified portfolio after the HIS separation leaves a clearer, more focused operating base where MedSurg now drives roughly 64% of revenue and Dental and HIS each contribute 18%, making execution easier to evaluate and margin expansion more visible. The company has already shown strong underlying demand, with 2Q26 revenue of $2.209B, 9.5% organic growth, and adj. EPS of $2.55, while management still sees 4%–5% organic growth, a 9% CAGR in adj. EPS, and more than $1B in FY27 FCF as separation costs roll off. Fundamental upside also comes from underpenetrated MedSurg categories like NPWT and advanced wound care, Acera Surgical’s early contribution, and mix-rich Dental growth supported by new products and SKU rationalization.

Bear case

Solventum is viewed negatively because its growth outlook appears modest relative to peers, with FY26 organic revenue growth guided to just 2.5% to 3.0% and roughly 3.5% to 4.0% excluding SKU exit impact, while the business remains concentrated in medsurg at about 64% of revenue. The company also faces execution risk as it works through separation of its HIS segment, and downside could stem from slower operating margin expansion, higher competition, and rising interest expense if rates remain elevated. Although management raised FY26 EPS to $7.10 to $7.20 and adjusted operating margin to 22.2% to 22.7%, the stock still screens as a lower-growth story versus peers trading at about 16.8x P/E.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.